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FLAVOCOXID ACTS VIA AN ANTI-PEROXIDASE ACTIVITY ON
CYCLOOXYGENASE ENZYMES, 5-LIPOXYGENASE INHIBITION AND A
STRONG ANTIOXIDANT ACTIVITY TO MANAGE OSTEOARTHRITIS
B.P. Burnett1, L. Pillai1, A. Bitto2, F. Squadrito2, R.M. Levy1
1Primus Pharmaceuticals, Inc., Scottsdale, AZ; 2Universtiy of Messina, Messina,
Italy
Purpose: Flavocoxid, a USFDA-regulated, prescription medical food for the
clinical dietary management of osteoarthritis (OA) under the supervision
of a physician, shows equivalent eﬃcacy to NSAIDs in clinical studies
with fewer side effects. Its exact mechanism of action, however, is poorly
understood. The aim of these studies is to characterize ﬂavocoxid’s per-
oxidase/cyclooxygenase inhibition of cyclooxygenase-1 (COX-1) and COX-2
as well as its anti-5-lipoxygenase (5-LOX) activity. In addition, ﬂavocoxid’s
antioxidant capacity is determined along with its effect on inducible
inﬂammatory gene expression.
Methods: Puriﬁed enzymes were used to assess ﬂavocoxid’s anti-
peroxidase and anti-cyclooxygenase activity on COX-1 and COX-2 as
well as inhibitory activity on 5-LOX. Multiple standard antioxidant assay
assays were utilized to judge ﬂavocoxid’s antioxidant capacity and cell
co-culture of LPS-stimulated human peripheral blood mononuclear cells
(PBMCs) with ﬂavocoxid for its effect on inducible inﬂammatory gene
expression of COX-2, interleukin-1beta (IL-1β), IL-6 and tumor necrosis
factor-alpha (TNFα) as well as nuclear factor-kappa B (NF-κB).
Results: Flavocoxid showed balanced inhibition of COX-1 and COX-
2 peroxidase activities with inhibitory concentrations (IC50s) of 12.3
and 11.3μg/ml, respectively, while the 5-LOX IC50 was 110μg/ml. No
detectable 5-LOX inhibition was found for rofecoxib, celecoxib, valde-
coxib, diclofenac, meloxicam, naproxen, ibuprofen or aspirin. Flavo-
coxid showed minimal inhibition of cyclooxygenase activity for COX-1
(IC50=25μg/ml) compared to indomethacin (IC50=0.012μg/ml) and no
detectable cyclooxygenase inhibition of COX-2 compared to NS-398
(IC50=0.095μg/ml). Flavocoxid also demonstrated a strong antioxidant
capacity against a variety of reactive oxygen species: oxygen radical
absorbance capacity, ORAChydro=3700 μmolTE/g; ORAClipo= 19μmolTE/g;
ferric reducing/antioxidant power, FRAP=1145μmolTE/g; hydroxyl radi-
cal absorbance capacity, HORAC= 1326μmolCAE/g; peroxynitrite radical
averting capacity, NORAC=1936μmolTE/g; superoxide radical averting ca-
pacity, SORAC= 27kunitSODeq/g; trolox equivalent antioxidant capacity,
TEAC=2456μmolTE/g; and 2,2-di(4-tert-octylphenyl)-1-picrylhydroxyl ca-
pacity, DPPH=767μmolTE/g. In lipopolysaccharide-stimulated PBMCs, ﬂavo-
coxid strongly reduced gene expression of COX-2 (80-fold), TNFα (11-fold),
IL-1β (10-fold) and IL-6 (40-fold) and, to a lesser extent, COX-1 (2.8-fold).
Expression of NF-κB gene was also reduced (2.2-fold).
Conclusions: These results suggest that the clinically favorable effects
and equivalency to NSAIDs in the management of OA are more than
likely achieved by simultaneous modiﬁcation at multiple points in the
inﬂammatory process making ﬂavocoxid a unique anti-inﬂammatory acting
via antioxidant mechanisms both on the cyclooxygenase enzyme and in
damping inducible, inﬂammatory gene expression. Flavocoxid also acts
through direct inhibition of 5-LOX to avoid a shunting of arachidonic acid
metabolism toward leukotriene production.
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MEDICATION USE IN THE OSTEOARTHRITIS INITIATIVE (OAI) STUDY
F. Saunders, K. Giles, R.M. Aspden, J.S. Gregory
Univ. of Aberdeen, Aberdeen, United Kingdom
Purpose: The purpose of this study was to determine the frequency of
prescription and the changes in prescribing patterns within the total cohort
and three sub-cohorts of the OAI study.
Methods: Information was collected at baseline, 12, 24 and 36 month clinic
visits and medication data were sorted by major drug classes, focussing
on NSAIDs, Statins and Bisphosphonates, chosen as they are known to
be associated with musculoskeletal diseases in each of the three cohorts
(Progression, Incidence and Control). Chi-squared statistics were used to
compare groups at baseline and 36 months.
Results: All cohorts contained more women than men and women were
prescribed more items than men at all timepoints and in all cohorts except
the control cohort at 36 months.
Figure 1 shows the major trends between cohorts and over time. Analysis
Figure 1
showed a signiﬁcant increase in prescriptions of Statins from baseline to
3 years follow-up (from 26% to 36% of total cohort [n=4796 at baseline]
(P<0.0001)). Atorvastatin prescription numbers did not change but there
were increases in Simvastatin and Lovostatin prescription numbers in both
the Progression and Incidence cohorts over time. There was a signiﬁcant
reduction in prescription of NSAIDs (P<0.05) although there was a 12.5%
reduction in prescriptions of Alendronate.There was a decreasing trend
for the prescription of anti-depressant drugs. This was noticeable in the
prescriptions of Fluoxetine and Paroxetine which both decreased over
time. Three subjects were noted to be on antiretroviral medication which,
according to the FDA list of side effects, can result in severe bone loss.
Opioid drug prescriptions did not change signiﬁcantly over time.
The proportion of medications prescribed for each cohort varied signiﬁ-
cantly for each of the three drug groups (P<0.001). Fewer Bisphosphonates
were prescribed in the Progression group (7%) compared to the Incidence
(11%) or Control (10%) groups. Both Statin and NSAID prescriptions were
highest in the Progression group (28% and 39% respectively), followed by
the Incidence (26% and 26%) and Control groups (11% and 9%).
Conclusions: During the 3 years of this study, prescriptions of Statins
signiﬁcantly increased, NSAID prescriptions signiﬁcantly decreased whilst
Bisphosphonate prescriptions remained stable. The increase in prescrip-
tions of Statins may reﬂect a general rise in the tendency to prescribe
this medication in the ‘normal’ population. The reduction in COX-2 speciﬁc
NSAIDS may be due to the withdrawal of Rofecoxib and limitations placed
on the prescription of other COX-2 inhibitors.
There are drugs which we have considered under their major drug classi-
ﬁcation which may be prescribed for other purposes, such as Gabapentin
which has been classiﬁed as treatment for epilepsy but can also be
prescribed for severe neuropathic pain.
The changes in prescription use between the cohorts and over time should
be borne in mind for all analysis. Bisphosphonate use is of particular
interest, as it shows a large number of the cohort (over 450 subjects) are
taking medication designed to increase bone density which may affect their
OA status and progression in unknown ways.
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ANTI-INFLAMMATORY ACTIVITY OF AN ETHANOLIC CAESALPINIA SAPPAN
EXTRACT IN HUMAN CHONDROCYTES IN VITRO
S. Wu1, F. Unger1, M. Goldring2, H. Viernstein1, S. Toegel1
1Dept. of Pharmaceutical Technology and Biopharmaceutics, Vienna, Austria;
2Hosp. for Special Surgery, Weill Cornell Med. Coll., New York, NY
Purpose: Extracts from Caesalpinia sappan as well as their main con-
stituents have been reported to exhibit anti-inﬂammatory, antioxidant,
antibacterial and immunosuppressive activities in different tissues. Given
their inhibitory effect on inﬂammatory cytokines and mediators, compo-
nents of Caesalpinia sappan might be potential drug candidates for disease
modiﬁcation in osteoarthritis (OA). The aim of this study was to evaluate
the anti-inﬂammatory effects of an ethanolic extract from Caesalpinia
sappan (CSE) in an osteoarthritic chondrocyte model.
Methods: CSE was prepared by continuous extraction with ethanol for
24 h. The quality and stability of CSE from different batches was veriﬁed
S254 Poster Presentations / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S45–S256
by HPLC. SW1353 and primary human chondrocytes obtained after total
knee replacement surgery from patients with osteoarthritis (OA) were
cultured in DMEM with 10% FCS. Cytotoxicity of different CSE concentra-
tions was examined using MTT and BrdU assays. Quantitative real-time
RT-PCR (RT-qPCR) was used to evaluate the effects of CSE on mRNA
levels of interleukin-1-beta (IL-1β), tumor necrosis factor-alpha (TNF-α), in-
ducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and matrix
metalloproteinase-3 (MMP-3). The nitric oxide (NO) production was mea-
sured using Griess assay. The gelatinolytic activity of MMPs was determined
by zymography. Transient transfection and luciferase assay was performed
to study CSE action on NF-kappaB signalling.
Results: Dose-response experiments revealed that up to 20 μg/ml CSE did
not impair viability of chondrocytes. CSE treatments (5-20 μg/ml) signif-
icantly suppressed the up-regulation of proinﬂammatory cytokine mRNA
(IL-1β and TNF-α) in response to IL-1β (10 ng/ml) stimulation in SW1353
and primary chondrocytes (p<0.05). At the same concentrations, CSE in-
hibited the IL-1β induced up-regulation of MMP3 mRNA and gelatinolytic
activity of MMPs in a dose-dependent manner. A signiﬁcant inhibition of
NO production and iNOS mRNA expression was also observed in IL-1β
stimulated primary chondrocytes pretreated with CSE (p<0.05). Cotrans-
fections of the COX-2 promoter luciferase reporter plasmid together with
p50 and p65 expression vectors enhanced the COX-2 promoter activity
3.4-fold in SW1353 cells. This p50/p65-mediated transactivation of the
COX-2 promoter was dose-dependently down-regulated to basal levels by
CSE.
Conclusions: These results indicate that CSE possesses potent anti-
inﬂammatory activity in osteoarthritic chondrocytes. In particular, its
action might involve the inhibition of NO production via iNOS downreg-
ulation as well as the inhibition of p50/p65-mediated COX-2 promoter
activation.
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MODULATION OF CHONDROCYTE METABOLIC PATHWAYS BY NSAIDS
AND THE CYCLOOXYGENASE-INHIBITING NITRIC OXIDE DONATOR
(CINOD) NCX 429
L. Maneix1, D. Ollitrault1, N. Bigot1, E. Duval1, M. Bolla2, S. Viappiani2,
K. Boumediene1
1Univ. of Caen, Caen, France; 2Nic Ox SA, Sophia Antipolis, France
Purpose: Osteoarthritis (OA) progression is accompanied by a reduction
of extracellular matrix and increased catabolism of collagen ﬁbers and
glycosaminoglycans in joints. Cyclooxygenase-inhibiting nitric oxide dona-
tors (CINODs) are novel anti-inﬂammatory compounds designed to provide
balanced COX-1 and COX-2 inhibition while releasing nitric oxide (NO),
an important modulator of vascular tone. In the cartilage, the role of
NO is controversial, as it is a recognized marker of inﬂammation and a
possible cause of chondrocyte loss, but also a potent immuno-modulating
factor improving joint vascular perfusion. We investigated the effects of the
CINOD NCX 429 and reference NSAIDs (naproxen and celecoxib) in stim-
ulated adult rabbit chondrocytes, focusing on their catabolic and anabolic
activities, as well as inﬂammatory parameters.
Methods: Primary cultures of adult rabbit (4-6 months) articular chondro-
cytes (RACs) were pre-incubated with test drugs (1-10 μM, 8 hours) before
addition of IL-1β (10 ng/ml, 16 additional hours) in 5% O2 conditions, to
mimic joint limited perfusion. Levels of mRNA were determined by quan-
titative RT-PCR for assessing expression of extracellular matrix proteins
(aggrecan and collagen type II) and matrix proteases [aggrecanases and
matrix metalloproteases (MMPs)]. NO production was determined by mea-
surement of nitrite/nitrate (NOx) using the Griess method. Type II collagen
production was evaluated in the supernatant by Western blot analysis. To
assess COX inhibition, prostaglandin E2 (PGE2) was measured by enzyme
immunoassay in the supernatant of IL-1β stimulated chondrocytes (from 2
months-old rabbits) incubated with NCX 429 (1-100 μM).
Results: NCX 429 and naproxen did not show any impact on RAC viability.
In IL-1β-stimulated RACs, NCX 429 induced a 2-fold increase in type II col-
lagen expression, similarly to naproxen and celecoxib. NCX 429 stimulated
type II collagen at both mRNA and protein levels. In addition, NCX 429 re-
duced IL-1β-stimulated expression of MMP-1 by ∼ 50% and aggrecanase-1
and 2 expression (by ∼ 50% and 40%, respectively), with similar eﬃcacy
to naproxen and celecoxib. Conversely, IL-1β-induced increase in MMP-3
and decrease in aggrecan expression were not prevented by NCX 429 or
naproxen, whereas celecoxib inhibited MMP-3 expression by 40%. Inter-
estingly, while naproxen and celecoxib increased IL-1β-stimulated NOx
levels by ∼ 50 and 30%, respectively, NCX 429 decreased NOx levels (by
∼ 25%). Finally, NCX 429 inhibited IL-1β-induced PGE2 biosynthesis in a
concentration-dependent manner, indicating effective COX inhibition.
Conclusions: NCX 429, naproxen and celecoxib modulate IL-1β-induced
expression of catabolic and anabolic markers in stimulated adult rabbit
articular chondrocytes. Interestingly, the CINOD NCX 429 slightly reduces
IL-1β-induced increase of endogenous NO synthesis, differently from the
other NSAIDs, likely by inhibiting inducible nitric oxide synthase (iNOS)
expression, as already reported for other CINODs. NO has been considered
as potentially detrimental for chondrocytes; however, donation of low
concentrations of NO from the CINOD NCX 429 does not seem to affect
chondrocyte survival or to increase the expression of mediators involved
in cartilage degeneration. CINODs may even inhibit endogenous overpro-
duction of NO, and therefore may represent an interesting therapeutic
approach for the treatment of osteoarthritis.
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EFFECTS OF RIBONUCLEINATE COMPONENTS OF OSTEOCHONDRINR S
OSTEOARTHRITIS THERAPY ON FORMATION AND ACTIVITY OF HUMAN
OSTEOCLASTS IN VITRO
M. Cantley1, D.R. Haynes1, K.D. Rainsford2
1Univ. of Adelaide, Adelaide, Australia; 2Sheﬃeld Hallam Univ., Sheﬃeld,
United Kingdom
Purpose: To establish if the ribonucleinate components of the osteo-
arthritis natural drug, Osteochondrin® S (OST) affect the bone-resorbing
functions and gene expression in osteoclasts.
Methods: Human osteoclasts were generated in vitro from culture of
RANKL-M-CSF stimulated peripheral blood mononuclear cells for 17d. Cells
were treated with 23.5-587.2 ng/mL OST or 0.2-5 mg/mL RNA components
of connective tissues or yeast (as used to make OST) and their effects on
osteoclast formation were assessed using a Tartrate-Resistant Acid Phos-
phatase (TRAP) stain. Cell were also grown on dentine slices and used to
determine the effects on osteoclast bone resorption was The pit formation
on dentine was determined by scanning electron microscopy. In separate
experiments, real time PCR was used to determine mRNA expression of
principal enzymes or signalling molecules governing osteoclast functions.
Results: OST and its RNA components showed approximately equiva-
lent concentration-dependent inhibition of TRAP stained osteoclasts and
associated reduction in pit formation on dentine (Fig. 1A–F).
OST was, however, more potent in preventing bone resorption than the
individual RNAs. mRNA expression of calcitonin receptor (CTR) was reduced
Figure 1A–F: Effects of OST and RNA components on osteoclast-mediated bone resorp-
tion. Statistical signiﬁcance (***p<0.001; *p<0.05) - one-way ANOVA.
